Suppr超能文献

对镶嵌型人类免疫缺陷病毒1型包膜DNA疫苗的T细胞应答广度扩大。

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.

作者信息

Kong Wing-Pui, Wu Lan, Wallstrom Timothy C, Fischer Will, Yang Zhi-Yong, Ko Sung-Youl, Letvin Norman L, Haynes Barton F, Hahn Beatrice H, Korber Bette, Nabel Gary J

机构信息

Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA.

出版信息

J Virol. 2009 Mar;83(5):2201-15. doi: 10.1128/JVI.02256-08. Epub 2008 Dec 24.

Abstract

An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.

摘要

一种有效的艾滋病疫苗必须能够控制人类免疫缺陷病毒1型(HIV-1)高度多样的流行毒株。在HIV-1基因产物中,包膜(Env)蛋白包含可变区和保守区。在本报告中,测试了一种针对HIV-1 Env M组全球序列设计T细胞疫苗的信息学方法。合成Env抗原被设计用于表达嵌合体,以最大限度地纳入常见的潜在T细胞表位(PTE)9肽,并尽量减少可能引发毒株特异性反应的罕见表位的纳入。使用细胞内细胞因子染色,在近交小鼠中用一组高度保守的15肽PTE肽对DNA疫苗进行评估。开发了增加理论表位覆盖率的一嵌合体、二嵌合体和三嵌合体组合。将这些疫苗刺激的T细胞免疫的广度和强度与天然毒株Env的进行比较;对突变Env进行了额外比较,包括有或没有V区的gp160或gp145以及gp41缺失。其中,二嵌合体或三嵌合体Env组合引发了最佳的CD4和CD8反应。这些反应在CD8 T细胞中最为明显;三嵌合体组合引发了对平均八个肽池的反应,而一组三种天然Env引发的反应针对两个肽池。因此,合成嵌合HIV-1抗原可以诱导具有更广泛广度的T细胞反应,并可能促进基于T细胞的有效HIV-1疫苗的开发。

相似文献

1
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.
J Virol. 2009 Mar;83(5):2201-15. doi: 10.1128/JVI.02256-08. Epub 2008 Dec 24.
3
Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.
J Virol. 2015 Jan 15;89(2):1195-204. doi: 10.1128/JVI.02370-14. Epub 2014 Nov 5.
6
HIV Env conserved element DNA vaccine alters immunodominance in macaques.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2859-2871. doi: 10.1080/21645515.2017.1339852. Epub 2017 Jul 5.
8
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.
Nat Med. 2010 Mar;16(3):319-23. doi: 10.1038/nm.2089. Epub 2010 Feb 21.

引用本文的文献

1
Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.
Mol Ther Methods Clin Dev. 2021 May 5;21:741-753. doi: 10.1016/j.omtm.2021.04.018. eCollection 2021 Jun 11.
2
Graph-theoretical formulation of the generalized epitope-based vaccine design problem.
PLoS Comput Biol. 2020 Oct 23;16(10):e1008237. doi: 10.1371/journal.pcbi.1008237. eCollection 2020 Oct.
3
A Zigzag but Upward Way to Develop an HIV-1 Vaccine.
Vaccines (Basel). 2020 Sep 8;8(3):511. doi: 10.3390/vaccines8030511.
4
Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.
Vaccines (Basel). 2020 Jun 3;8(2):273. doi: 10.3390/vaccines8020273.
6
Strategies for inducing effective neutralizing antibody responses against HIV-1.
Expert Rev Vaccines. 2019 Nov;18(11):1127-1143. doi: 10.1080/14760584.2019.1690458. Epub 2019 Dec 2.
9
Conserved HIV Epitopes for an Effective HIV Vaccine.
J Clin Cell Immunol. 2017 Aug;8(4). doi: 10.4172/2155-9899.1000518. Epub 2017 Aug 30.
10
Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-8. doi: 10.1080/21645515.2017.1281487. Epub 2017 Mar 16.

本文引用的文献

1
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.
J Exp Med. 2008 Oct 27;205(11):2537-50. doi: 10.1084/jem.20081524. Epub 2008 Oct 6.
3
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10489-94. doi: 10.1073/pnas.0803352105. Epub 2008 Jul 23.
4
Web-based design and evaluation of T-cell vaccine candidates.
Bioinformatics. 2008 Jul 15;24(14):1639-40. doi: 10.1093/bioinformatics/btn251. Epub 2008 May 29.
5
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.
7
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity.
Science. 2007 Aug 10;317(5839):825-8. doi: 10.1126/science.1135165.
8
Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
J Virol. 2007 Aug;81(16):8507-14. doi: 10.1128/JVI.02683-06. Epub 2007 May 30.
9
Coping with viral diversity in HIV vaccine design.
PLoS Comput Biol. 2007 Apr 27;3(4):e75. doi: 10.1371/journal.pcbi.0030075.
10
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Vaccine. 2007 May 16;25(20):4085-92. doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验